[go: up one dir, main page]

PE20090512A1 - Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53 - Google Patents

Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53

Info

Publication number
PE20090512A1
PE20090512A1 PE2008001310A PE2008001310A PE20090512A1 PE 20090512 A1 PE20090512 A1 PE 20090512A1 PE 2008001310 A PE2008001310 A PE 2008001310A PE 2008001310 A PE2008001310 A PE 2008001310A PE 20090512 A1 PE20090512 A1 PE 20090512A1
Authority
PE
Peru
Prior art keywords
mdm2
interaction
inhibitors
compound
phenylenediamines
Prior art date
Application number
PE2008001310A
Other languages
English (en)
Inventor
Alain Philippe Poncelet
Bruno Schoentjes
Virginie Sophie Poncelet
Pierre-Henri Storck
Carina Leys
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20090512A1 publication Critical patent/PE20090512A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA UN COMPUESTO DE FORMULA (I) EN FORMA DE N- OXIDO, UNA SAL DE ADICION, UNA FORMA ISOMERICA TAL COMO ENANTIOMERO S O R, Y SU FORMA POLIMORFICA QUE COMPRENDE PICOS DE DIFRACCION EN POSICION DOS- TETHA DE 6,4‘+-0,2‘, 12,8‘+-0,2‘, 15,2‘+-0,2‘ Y 17,3‘+-0,2‘. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCESO DE PREPARACION. DICHO COMPUESTO ES INHIBIDOR DE UNA INTERACCION ENTRE P53-MDM2 UTIL EN EL TRATAMIENTO DE TUMORES Y CANCER
PE2008001310A 2007-08-06 2008-08-06 Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53 PE20090512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113878 2007-08-06

Publications (1)

Publication Number Publication Date
PE20090512A1 true PE20090512A1 (es) 2009-04-29

Family

ID=38872012

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001310A PE20090512A1 (es) 2007-08-06 2008-08-06 Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53

Country Status (10)

Country Link
US (1) US8853406B2 (es)
EP (1) EP2185541B1 (es)
AR (1) AR067813A1 (es)
CL (1) CL2008002316A1 (es)
ES (1) ES2534899T3 (es)
PA (1) PA8792401A1 (es)
PE (1) PE20090512A1 (es)
TW (1) TW200922557A (es)
UY (1) UY31273A1 (es)
WO (1) WO2009019274A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
MY152018A (en) 2009-02-04 2014-08-15 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
TW201932456A (zh) 2013-01-15 2019-08-16 美商英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN110291087B (zh) 2016-12-01 2024-07-09 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
AR123492A1 (es) * 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
BR9915940A (pt) 1998-12-02 2001-09-11 Pfizer Prod Inc Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
JP2004508421A (ja) 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
AU2002357728A1 (en) 2001-11-09 2003-05-19 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
PL370176A1 (en) 2001-11-13 2005-05-16 3-Dimensional Pharmaceuticals, Inc. Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
ES2301717T3 (es) 2001-12-18 2008-07-01 F. Hoffmann-La Roche Ag Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores.
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
JP5156378B2 (ja) 2004-09-22 2013-03-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤

Also Published As

Publication number Publication date
EP2185541B1 (en) 2015-01-28
ES2534899T3 (es) 2015-04-30
CL2008002316A1 (es) 2009-07-17
UY31273A1 (es) 2009-03-02
WO2009019274A1 (en) 2009-02-12
TW200922557A (en) 2009-06-01
AR067813A1 (es) 2009-10-21
PA8792401A1 (es) 2009-03-31
US8853406B2 (en) 2014-10-07
EP2185541A1 (en) 2010-05-19
US20110130418A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
PE20090512A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
MX2009002306A (es) Nuevos inhibidores de mdm2 de molecula pequeña y sus usos.
MX2007010272A (es) Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
CU20090206A7 (es) Solución novedosa no-acuosa tópica de diclofenaco y proceso para su preparación
SG171682A1 (en) Iap bir domain binding compounds
LU92338I2 (fr) Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI)
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
ATE522518T1 (de) Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
MX2010004493A (es) Compuestos de tropano.
UA109417C2 (uk) ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
EA200970856A1 (ru) Ингибиторы пути хеджхога
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
PH12012500870A1 (en) Spiro-oxindole mdm2 antagonists
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2009005934A (es) Compuestos organicos.
JO2848B1 (en) Organic compounds
BR112012026289A2 (pt) composto orgânico para uso no tratamento de câncer do fígado
PA8850801A1 (es) Compuestos útiles para inhibir chk1
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
TNSN07419A1 (en) Methods for treating drug resistant cancer
EP2132013A4 (en) THIN METAL NANODRESSES MANUFACTURED BY BIOTEMPLATING
CR10270A (es) Medicamentos que contienen fluoroquinolonas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed